STXS News & Events

Stereotaxis announced that it has entered into a definitive agreement to acquire Robocath. Stereotaxis estimates that Robocath will contribute approximately $2M in annual revenue during the first year post-acquisition. The acquisition is expected to become breakeven by the third year post-acquisition, supported by commercial and operational synergies. The transaction consideration includes an upfront payment of $20M, and additional contingent payments of up to $25M tied to regulatory and commercial milestones, including FDA clearance of Robocath's next generation system. Consideration is payable in cash or Stereotaxis common stock, at Stereotaxis' discretion. The acquisition is subject to customary closing conditions and is expected to close in mid-2026. Upon closing, Robocath will operate as a wholly owned subsidiary of Stereotaxis.

Stereotaxis announced that it has received FDA 510(k) clearance for the Synchrony system. "Synchrony and SynX are central to our digital surgery efforts to modernize the interventional lab with enhanced workflow, remote connectivity, and smart AI capabilities," said David Fischel Stereotaxis chairman and CEO. "The technology improves the robotic cockpit, and will be critical in supporting robotic efforts for remote long-distance procedures and automated catheter navigation. The opportunity is much broader than robotic labs as we believe all cath labs stand to benefit from improved workflow, connectivity, and collaboration."